Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01052012




Registration number
NCT01052012
Ethics application status
Date submitted
18/01/2010
Date registered
20/01/2010
Date last updated
1/06/2021

Titles & IDs
Public title
Bupivacaine Effectiveness and Safety in SABER® Trial
Scientific title
Bupivacaine Effectiveness and Safety in SABER Trial (BESST)
Secondary ID [1] 0 0
C803-025
Universal Trial Number (UTN)
Trial acronym
BESST
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Postoperative Pain 0 0
Abdominal Surgery 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SABER-Bupivacaine
Treatment: Drugs - Bupivacaine HCl
Treatment: Drugs - SABER-Placebo

Experimental: Active: SABER-Bupivacaine - SABER-Bupivacaine

Active comparator: Comparator: Bupivacaine HCl - Bupivacaine HCl

Placebo comparator: Placebo: SABER-Placebo - SABER-Placebo


Treatment: Drugs: SABER-Bupivacaine
Injectable Extended Release Solution; SABER-Bupivacaine /Once

Treatment: Drugs: Bupivacaine HCl
Injectable Solution; Bupivacaine HCl /Once

Treatment: Drugs: SABER-Placebo
Injectable Solution; SABER-Placebo/Once
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean Pain Intensity on Movement
Timepoint [1] 0 0
0 to 72 hours post-dose
Primary outcome [2] 0 0
Supplemental Opioid Use
Timepoint [2] 0 0
0-72 hours post dose
Secondary outcome [1] 0 0
Mean Pain Intensity on Movement
Timepoint [1] 0 0
0 to 48 hours post-dose
Secondary outcome [2] 0 0
Total Morphine-equivalent Dose
Timepoint [2] 0 0
0-48 hours post dose
Secondary outcome [3] 0 0
Proportion (Percent) of Patients Who Have Evidence of a Wound Infection
Timepoint [3] 0 0
0 to 14 days post-dose (Visits 3 and 4)
Secondary outcome [4] 0 0
Time-to-first Use of Opioid Rescue Medication
Timepoint [4] 0 0
0 to 14 days post-dose (Time from extubation until first opioid use)
Secondary outcome [5] 0 0
Number (Incidence) of Participants With Opioid-related Side Effects
Timepoint [5] 0 0
0 to 30 days post-dose
Secondary outcome [6] 0 0
Pain Intensity at Rest AUC During 0-72 Hours Post Dose
Timepoint [6] 0 0
0-72 hours post dose
Secondary outcome [7] 0 0
Mean Pain Intensity at Rest AUC During 0-48 Hours Post Dose
Timepoint [7] 0 0
0-48 hours post dose

Eligibility
Key inclusion criteria
* Patients must be able to read and understand the consent form, provide written consent, complete trial-related procedures, and communicate with the trial staff
* Males and females, 18 years of age and older scheduled to undergo elective general abdominal surgery
* Patients must be healthy or have only mild systemic disease
* BMI < 45
* Patients must have ECG wave form within normal limits
* Female and male patients must agree to use medically acceptable method of contraception throughout the entire trial period and for 1 week after the trial participation is completed
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients who are pregnant or lactating
* Patients undergoing emergency surgery (unless full consent is obtained and all screening procedures are completed prior to surgery)
* Significant concomitant surgical procedure
* History of multiple prior laparotomy procedures
* Cancer with known metastases pre-operatively, which are suspected to impact post-operative recovery or pain
* Planned formation of stoma during surgery or plans to undergo another laparotomy procedure within 30 days post-operatively
* Pre-operative evidence of sepsis or septic shock
* Pre-operative evaluation that suggests a surgery may preclude full closure of the incision(s)
* Patients with current or regular use of systemic steroids, anticonvulsants, antiepileptics, antidepressants, or monoamine oxidase inhibitors, who cannot be withdrawn from these medications
* Patients with current or regular use of drugs known to significantly prolong the QTc interval
* Patients with known hypersensitivity to local anesthetic agents of the amide type (e.g. lidocaine, bupivacaine)
* Patients with known hypersensitivity to morphine
* Patients with conditions contraindicated for use of opioids
* Patients with atrial fibrillation/flutter or other non-sinus rhythm (including paced rhythm); left bundle branch block (LBBB); or the following conditions: right bundle branch block (RBBB) in presence of a cardiac disease, significant cardiomyopathy, and myocardial infarction within last 6 months
* Patients with a serum creatinine level two times more than the local laboratory normal limit
* Patients who have received greater than 600 mg morphine equivalent daily dose for three or more days per week in the month prior to the surgical procedure
* Patients who are currently being treated with methadone, or history of methadone use within the previous 6 months
* Patients with known or suspected abuse of opioids or other illicit drugs
* Patients with known or suspected alcohol abuse
* Participation in another clinical trial at the same time or within 30 days of this trial
* Patients who, in the Investigator's opinion, should not participate in the trial or may not be capable of following the trial schedule for any reason

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/12/2009
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/09/2011
Sample size
Target
Accrual to date
Final
331
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
DURECT Study Site - Woodville South
Recruitment hospital [2] 0 0
DURECT Study Site - Box Hill
Recruitment hospital [3] 0 0
DURECT Study Site - Ringwood East
Recruitment postcode(s) [1] 0 0
5011 - Woodville South
Recruitment postcode(s) [2] 0 0
3128 - Box Hill
Recruitment postcode(s) [3] 0 0
3135 - Ringwood East
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Georgia
Country [5] 0 0
United States of America
State/province [5] 0 0
Indiana
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Michigan
Country [8] 0 0
United States of America
State/province [8] 0 0
Minnesota
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
North Carolina
Country [11] 0 0
United States of America
State/province [11] 0 0
Ohio
Country [12] 0 0
United States of America
State/province [12] 0 0
Pennsylvania
Country [13] 0 0
United States of America
State/province [13] 0 0
Texas
Country [14] 0 0
New Zealand
State/province [14] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Durect
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
Nycomed
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Hospira, now a wholly owned subsidiary of Pfizer
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Dmitri Lissin, MD
Address 0 0
Durect
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT01052012